Results 21 to 30 of about 20,264 (293)
Frontiers in Pharmacology, 2023 Objective: Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging.
Guoliang Deng +11 more
doaj +1 more source
Physiologically based pharmacokinetic (PBPK) model of talinolol
, 2023 <p>This repository provides the talinolol physiologically based pharmacokinetic (PBPK) model.</p> <p>If you have any questions or problems please <a href="https://github.com/matthiaskoenig/talinolol-model/issues">open an issue</
Stemmer Mallol, Beatrice Amelie +1 more
core +2 more sources
Fluids and Barriers of the CNS, 2022 Blood biomarkers of neurological diseases are often employed to rule out or confirm the presence of significant intracranial or cerebrovascular pathology or for the differential diagnosis of conditions with similar presentations (e.g., hemorrhagic vs ...
Robert Murcko +3 more
doaj +1 more source
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies [PDF]
, 2015 Introduction: The pharmacokinetic properties of anti-infective drugs are a determinant part of treatment success. Pathogen replication is inhibited if adequate drug levels are achieved in target sites, whereas excessive drug concentrations linked to ...
Rajoli, Rajith K. R. +3 more
core +3 more sources
Pharmaceutics, 2022 Pregnancy is associated with physiological changes that may affect drug pharmacokinetics (PKs). The aim of this study was to establish a maternal–fetal physiologically based pharmacokinetic (PBPK) model of oxcarbazepine (OXC) and its active metabolite ...
Lixia He +7 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: Voriconazole is a potent antifungal drug with complex pharmacokinetics caused by time-dependent inhibition and polymorphisms of metabolizing enzymes. It also exhibits different pharmacokinetic characteristics between adults and children.
Yahui Zhang +7 more
doaj +1 more source
A physiologically based pharmacokinetic model for V937 oncolytic virus in mice
Frontiers in Pharmacology, 2023 Introduction: Oncolytic viruses (OVs) represent a novel therapeutic strategy in oncology due to their capability to selectively infect and replicate in cancer cells, triggering a direct and/or immune-induced tumor lysis. However, the mechanisms governing
Sara Peribañez-Dominguez +7 more
doaj +1 more source
An introduction to physiologically‐based pharmacokinetic models
Pediatric Anesthesia, 2016 SummaryPhysiologically‐based pharmacokinetic (PBPK) models represent drug kinetics in one or more ‘real’ organs (and hence require submodels of organs/tissues) and they describe ‘whole‐body’ kinetics by joining together submodels with drug transport by blood flow as dictated by anatomy.
Richard N. Upton +2 more
openaire +3 more sources
Frontiers in Pharmacology, 2022 Background: Propylthiouracil (PTU) treats hyperthyroidism and thyroid crisis in all age groups. A variety of serious adverse effects can occur during clinical use and require attention to its pharmacokinetic and pharmacodynamic characteristics in various
Chaozhuang Shen +7 more
doaj +1 more source
Physiologically Based Pharmacokinetic Modeling of Extracellular Vesicles
Biology, 2023 Extracellular vesicles (EVs) are lipid membrane bound-cell-derived structures that are a key player in intercellular communication and facilitate numerous cellular functions such as tumor growth, metastasis, immunosuppression, and angiogenesis. They can be used as a drug delivery platform because they can protect drugs from degradation and target ...
Prashant Kumar +2 more
openaire +3 more sources